세계의 임상화학 분석기 시장을 촉진하고 있는 것은 주로 인구의 고령화, 헬스케어 지출의 증가, POC(Point of Care) 검사 시설의 증가입니다. Verified Market Research의 애널리스트에 따르면 임상화학 분석기 시장은 2024년의 평가액 134억 6,000만 달러를 밑돌며, 2031년에는 182억 2,000만 달러의 평가액에 달할 것으로 예측됩니다.
질병의 조기 발견, 기술 발전으로 인한 검사 효율성 향상, 빈번한 모니터링이 필요한 만성질환의 유병률 증가가 세계의 임상화학 분석기 시장을 주도하고 있습니다. 이 때문에 시장은 2024-2031년 연평균 4.25%의 연평균 복합 성장률(CAGR)을 보일 것입니다.
임상화학분석기 시장 정의/개요
임상화학분석기는 혈액, 혈청, 소변, 뇌척수액 등 생체액의 화학 성분을 측정하는 자동 장치입니다. 이 분석기들은 분광광도법, 면역측정법, 전기화학법 등 다양한 기술을 이용하여 포도당, 전해질, 효소, 호르몬, 단백질 등의 분자의 양을 정량합니다.
또한 임상화학분석기는 당뇨병, 신장질환, 간질환, 대사이상 등 다양한 질환의 진단, 모니터링, 관리에 도움을 주고 있습니다. 일상적인 건강검진, 질병 진단, 치료 모니터링, 연구 활동에서 중요한 역할을 하며, 임상적 의사결정과 환자 치료 관리에 도움이 되는 정확하고 신속한 정보를 제공합니다.
당뇨병, 심혈관질환, 신장질환 등 만성질환의 확산으로 임상화학분석기기 수요가 증가하고 있습니다. 세계보건기구(WHO)에 따르면 만성질환은 전 세계 사망원인의 71%를 차지합니다. 국제당뇨병연맹에 따르면 성인 당뇨병 환자 수는 2021년 5억 3,700만 명에서 2045년 7억 8,300만 명으로 증가할 것으로 예측됩니다. 이러한 환자 수 증가로 인해 많은 생화학 마커의 빈번한 모니터링이 필요하게 되었고, 임상화학 분석기에 대한 수요가 증가하고 있습니다.
세계 노인 인구 증가는 임상화학 분석기 시장의 주요 촉진요인입니다. 유엔 경제사회국에 따르면 65세 이상 인구는 2019년 7억 3천만 명에서 2050년 15억 명으로 두 배로 증가할 것으로 예측됩니다. 노인들은 정기적인 의료 검사 및 모니터링이 자주 필요하므로 노화 관련 질환 및 만성질환 관리를 위해 임상화학분석기 사용이 증가하고 있습니다.
또한 효율성과 정확성을 향상시키는 기술의 발전으로 임상화학 분석기의 인기가 높아지고 있습니다. American Association for Clinical Chemistry(AACC)의 보고서에 따르면 병원 검사실에서 자동 임상화학 분석기 사용이 지난 5년간 30% 증가했다고 합니다. 이러한 최신 기술은 다수의 검사를 동시에 실행하고, 소요 시간을 단축하고, 인적 오류를 제거할 수 있으며, 의료시설에 더욱 매력적으로 다가와 시장 성장을 가속하고 있습니다.
첨단 임상화학 분석기, 특히 첨단 기술과 자동화 기능을 갖춘 분석기는 매우 고가입니다. 이러한 높은 초기 투자비용은 유지보수, 소프트웨어 업데이트, 시약 등의 정기적인 비용과 함께 특히 개발도상국의 중소규모 검사실 및 의료시설에 큰 장벽이 되고 있습니다. 이러한 경제적 장벽은 이들 지역에서 최신 진단기기의 접근과 사용을 가로막고 있습니다.
또한 고급 임상화학 분석기기의 작동, 데이터 분석, 유지보수를 위해서는 유능한 인재가 필요합니다. 매우 정교한 분석기기의 사용에는 가파른 학습 곡선이 수반되며, 상당한 교육이 필요합니다. 이는 유능한 검사 기술자가 부족하거나 지속적인 전문성 개발에 대한 접근이 제한되어 있는 지역에서는 큰 어려움을 초래할 수 있습니다.
The aging population primarily drives the global market for clinical chemistry analyzers, increased healthcare spending, and the growth of point-of-care testing facilities. According to the analyst from Verified Market Research, the clinical chemistry analyzers market is estimated to reach a valuation of USD 18.22 Billion by 2031 over the forecast subjugating around USD 13.46 Billion valued in 2024.
The demand for early disease detection, improvements in testing efficiency due to technological advancements, and the rising incidence of chronic diseases that necessitate frequent monitoring drive the global market for clinical chemistry analyzers. This enables the market to grow at a CAGR of 4.25% from 2024 to 2031.
Clinical Chemistry Analyzers Market: Definition/ Overview
Clinical chemistry analyzers are automated machines that measure the chemical components of biological fluids such as blood, serum, urine, and cerebrospinal fluid. These analyzers use various techniques, including spectrophotometry, immunoassays, and electrochemistry, to quantify the amounts of molecules such as glucose, electrolytes, enzymes, hormones, and proteins.
Furthermore, clinical chemistry analyzers help healthcare practitioners diagnose, monitor, and manage a wide range of medical diseases, including diabetes, renal disease, liver illnesses, and metabolic irregularities. They are critical in routine health screenings, disease diagnosis, treatment monitoring, and research efforts, giving accurate and fast information that aids clinical decision-making and patient care management.
What's inside a VMR industry report?
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
The growing prevalence of chronic diseases such as diabetes, cardiovascular ailments, and kidney disease is driving up demand for clinical chemistry analyzers. According to the World Health Organization (WHO), chronic diseases account for 71% of all deaths worldwide. According to the International Diabetes Federation, the number of adults with diabetes is anticipated to increase from 537 million in 2021 to 783 million by 2045. This rising patient population necessitates frequent monitoring of many biochemical markers, which increases the demand for clinical chemistry analyzers.
The growing older population worldwide is a major driver of the clinical chemistry analyzers market. According to the United Nations Department of Economic and Social Affairs, the number of people over the age of 65 is expected to double from 703 million in 2019 to 1.5 billion by 2050. Older persons frequently require more regular medical testing and monitoring, which has increased the usage of clinical chemistry analyzers for age-related illnesses and chronic disease management.
Furthermore, clinical chemistry analyzers are growing in popularity due to ongoing technical advancements that improve efficiency and accuracy. The American Association for Clinical Chemistry (AACC) reports that the use of automated clinical chemistry analyzers in hospital laboratories has increased by 30% in the last five years. These modern technologies can run numerous tests at the same time, shorten turnaround times, and eliminate human error, making them more appealing to healthcare facilities and boosting market growth.
Advanced clinical chemistry analyzers, particularly those with cutting-edge technology and automated capabilities, are highly expensive. This high initial investment cost, combined with recurring fees for maintenance, software updates, and reagents, is a considerable barrier for small to medium-sized laboratories and healthcare facilities, particularly in developing nations. This financial barrier hinders the availability and use of modern diagnostic equipment in these regions.
Furthermore, advanced clinical chemistry analyzers require competent individuals to operate, interpret data, and maintain them. The use of very sophisticated analyzers comes with a steep learning curve that requires substantial training. This presents a substantial difficulty in locations with a dearth of competent laboratory technicians or restricted access to ongoing professional development.
According to VMR Analysis, the reagent segment is estimated to hold the largest market share during the forecast period. Unlike analyzers, which are long-lasting capital equipment, reagents are consumables that must be replenished regularly. The need for reagents is ongoing and increases proportionally with the number of tests performed. This ongoing demand assures a consistent revenue stream for manufacturers and distributors, which contributes significantly to the segment's market share. As testing volumes increase due to the increased prevalence of chronic diseases and an aging population, so does the demand for reagents.
The extension of test menus to cover a wider range of biomarkers and specialized tests has resulted in an increase in the variety and complexity of reagents needed. Laboratories are constantly striving to provide more complete testing choices to clinicians and patients, which promotes the demand for specialized reagents. This diversification within the reagents segment can help it gain a bigger market share, as specialist reagents are frequently more expensive.
Furthermore, significant investment has been made in research and development within the reagents market to manufacture high-sensitivity and specificity reagents capable of detecting diseases at an earlier stage or improving result accuracy. These developments not only improve clinical results but also encourage the use of new testing procedures, increasing demand for these novel reagents.
The basic metabolic panel (BMP) segment is estimated to dominate the clinical chemistry analyzers market during the forecast period. Basic Metabolic Panels are a collection of tests that provide vital information about the body's metabolism, including blood glucose levels, calcium, electrolytes (such as sodium, potassium, and chloride), and kidney function markers (such as BUN and creatinine). Because of their comprehensive breadth, BMPs are commonly utilized in routine medical exams and patient screenings. This extensive use generates a strong demand for BMP testing, which contributes to its considerable market share.
BMPs are vital in emergency rooms and critical care units for quickly assessing a patient's metabolic status and organ performance. In life-threatening situations, quick BMP test findings can guide immediate treatment options for electrolyte imbalances, renal failure, diabetic ketoacidosis, and other conditions. The critical requirement for BMP testing in these circumstances maintains a sustained demand in the market.
Furthermore, the rising global prevalence of chronic diseases such as diabetes, hypertension, cardiovascular disease, and kidney disorders emphasizes the importance of frequent metabolic function monitoring. BMP tests are important in managing these disorders because they provide critical information on blood sugar levels, electrolyte and fluid balance, and renal function. As a result, the global rise in chronic health issues leads to the continued demand for BMP testing.
According to VMR Analyst, Asia Pacific is estimated to exhibit the highest growth within the clinical chemistry analyzers market during the forecast period. The Asia Pacific region's population is rapidly aging, resulting in a higher frequency of chronic diseases and an increased demand for diagnostic services. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the region's elder population (aged 65 and more) is predicted to more than double, from 548 million in 2019 to roughly 1.3 billion by 2050. This demographic transition is followed by an increase in chronic diseases, with the World Health Organization estimating that noncommunicable diseases account for 71% of all deaths in the Western Pacific region. The growing older population and chronic illness load are pushing up demand for clinical chemistry analyzers in healthcare facilities throughout the region.
Furthermore, the Asia Pacific region is experiencing an increase in emphasis on preventative healthcare and frequent health check-ups, which is driving demand for diagnostic services. According to a survey by the Asia Pacific Medical Technology Association (APACMed), the preventive health check-up market in India alone is estimated to reach USD 10.7 Billion by 2025, rising at a 27.5% CAGR over 2020. This trend is reflected throughout the region, with Prudential Corporation Asia reporting that 80% of Asians intend to improve their health in the next 24 months. This growing health consciousness is leading to greater use of clinical chemistry analyzers for routine health screenings and early disease diagnosis, which is contributing to the region's strong market growth.
North America is estimated to dominate the market during the forecast period. North America has a high prevalence of chronic disorders, which drives the demand for clinical chemistry analyzers. According to the Centers for Disease Control and Prevention (CDC), six out of every ten persons in the United States have a chronic disease, with four out of ten having two or more. According to the CDC, 34.2 million Americans (or 10.5% of the population) had diabetes in 2018. The high frequency of chronic illnesses needs frequent monitoring and testing, increasing demand for clinical chemistry analyzers in the region.
Furthermore, the increased popularity of point-of-care testing in North America is driving demand for compact and portable clinical chemistry analyzers. According to a National Center for Biotechnology Information research, the US point-of-care testing market is predicted to increase at a 6.8% CAGR between 2020 and 2027. According to the American Association for Clinical Chemistry (AACC), the usage of portable clinical chemistry analyzers in North American hospitals and clinics increased by 25% between 2018 and 2022 as a result of the shift toward quick, on-site testing.
The competitive landscape of the clinical chemistry analyzers market is characterized by fierce competition among prominent competitors attempting to extend their market position through tactics such as product innovation, strategic alliances, mergers and acquisitions, and regional expansion.
Some of the prominent players operating in the clinical chemistry analyzers market include:
Roche Diagnostics
Siemens Healthineers AG
Abbott Laboratories
Danaher Corporation
Thermo Fisher Scientific, Inc.
bioMerieux SA
Horiba Ltd.
Mindray Bio-Medical Electronics Co. Ltd
Tosoh Corporation
Hitachi
Shenzhen Mindray Bio-Medical Electronics Co
Alfa Wassermann Diagnostica Ltd
Erba Mannheim
Medica Corporation
Olympus Corporation
Transasia Bio-Medicals Ltd
In July 2023, Beckman Coulter Diagnostics gained FDA approval for the DxC 500 AU Chemistry Analyzer, an automated device intended for small- to medium-sized laboratories. The analyzer, with its standardized assays, improves clinical decision-making and patient outcomes with proven Six Sigma performance, boosting efficiency and reliability in diagnostic testing.
In December 2022, Abbott introduced the world's smallest implantable and rechargeable spinal cord stimulation system for chronic pain. Eterna SCS uses Abbott's low-dose BurstDR(TM) stimulation, which has the highest level of clinical evidence (1A) and has been shown to relieve pain by 23% more than standard waveform technology.